Qi Huang

TL;DR: In this article, the authors present a brief background information of nanoparticles as drug carriers, including but not limited to the types of nanomaterials, their biological properties and their advantages in clinical application.

TL;DR: The initial experience with TMPs-MTX in advanced lung cancer with MPE suggests that ATMPs targeting malignant cells and the immunosuppressive microenvironment may be a promising therapeutic platform for treating malignancies.

TL;DR: Emerging evidence indicates that IL‐17 not only has an oncogenic role in tumorigenesis by regulating tumor angiogenesis and enhancing tumor immune evasion but also exerts anti‐tumor functions by enhancing natural killer cells and cytotoxic T lymphocytes activation and through the recruitment of neutrophils, NK cells and CD4+ and CD8+ T cells to tumor tissue.

TL;DR: This review focuses on recent experimental and clinical studies investigating the basic properties, roles, and mechanisms of ACE2, Ang-(1–7), and the MasR, as well as the axis pathway, to provide insights into possible therapeutic strategies for treating cancer that target the ACE2/Ang-(1-7)/MasR axis.

TL;DR: IL-17 may promote the production of the angiogenic inducers IL-6, IL-8 and VEGF via STAT1 signalling in lung adenocarcinoma.